Nanox will announce Q3 2025 financial results on November 20, followed by a conference call for updates.
Quiver AI Summary
Nanox Imaging Ltd, a medical imaging technology company, announced it will release its financial results for the third quarter of 2025 on November 20, 2025, before the market opens. CEO Erez Meltzer and CFO Ran Daniel will discuss these results in a conference call at 8:30 a.m. ET, with access available via a registration link and a live webcast. The company focuses on advancing preventive healthcare through affordable medical imaging solutions powered by AI and a proprietary digital X-ray source. Nanox's offerings include cost-effective imaging systems, AI algorithms for enhancing CT readings, a cloud-based data management platform, and a decentralized marketplace for teleradiology services, all aimed at improving early disease detection and health outcomes. For more details, visit their website.
Potential Positives
- Nano-X Imaging is set to report its Q3 2025 financial results, providing transparency and accountability to investors by sharing their performance metrics.
- The upcoming conference call hosted by key executives aims to offer insights into both financial results and business updates, which can enhance investor relations.
- Nano-X's focus on preventive health care and advanced AI technology positions the company as a leader in innovative medical imaging solutions, appealing to potential investors and partners.
- The comprehensive ecosystem comprising various platforms and technologies demonstrates Nanox's commitment to improving health outcomes through accessible, cost-effective solutions.
Potential Negatives
- The press release does not provide any financial forecasts or expectations for the upcoming results, which may raise concerns about transparency and confidence in future performance.
- There is no mention of any recent accomplishments or advancements in technology, which could imply stagnation or challenges faced by the company.
- The schedule of the financial report seems to be significantly delayed, which might lead to speculation about underlying issues affecting timely disclosures.
FAQ
When will Nanox report its Q3 2025 financial results?
Nanox will report its financial results for Q3 2025 before market open on November 20, 2025.
How can I listen to the Nanox conference call?
Interested parties can register for the conference call via the provided link on the Nanox website.
What time is the Nanox Q3 2025 conference call scheduled?
The conference call is scheduled to begin at 8:30 a.m. ET on November 20, 2025.
What technologies does Nanox focus on?
Nanox focuses on affordable medical imaging technologies utilizing AI and proprietary digital X-ray sources.
Where can I find more information about Nanox's health solutions?
More information about Nanox's health solutions can be found on their official website at www.nanox.vision.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NNOX Insider Trading Activity
$NNOX insiders have traded $NNOX stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NNOX stock by insiders over the last 6 months:
- RAN DANIEL (CFO) purchased 1,000 shares for an estimated $3,650
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NNOX Hedge Fund Activity
We have seen 49 institutional investors add shares of $NNOX stock to their portfolio, and 68 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,160,806 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $11,171,367
- UBS GROUP AG removed 754,352 shares (-48.7%) from their portfolio in Q2 2025, for an estimated $3,899,999
- BLACKROCK, INC. added 385,806 shares (+11.6%) to their portfolio in Q2 2025, for an estimated $1,994,617
- MIRAE ASSET SECURITIES (USA) INC. removed 272,961 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,411,208
- GOLDMAN SACHS GROUP INC removed 212,011 shares (-65.9%) from their portfolio in Q2 2025, for an estimated $1,096,096
- NATIONAL BANK OF CANADA /FI/ added 123,900 shares (+35.1%) to their portfolio in Q2 2025, for an estimated $640,563
- GEODE CAPITAL MANAGEMENT, LLC added 120,460 shares (+17.5%) to their portfolio in Q2 2025, for an estimated $622,778
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NNOX Analyst Ratings
Wall Street analysts have issued reports on $NNOX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 09/19/2025
To track analyst ratings and price targets for $NNOX, check out Quiver Quantitative's $NNOX forecast page.
Full Release
PETACH TIKVA, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2025, before market open on Thursday, November 20, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Interested parties may register for the conference call using the following link: Nanox Q3 2025 Conference Call . The live webcast of the conference call may be accessed by using the following link : Nanox Q3 2025 Webcast .
The link will also be posted in the Investor Relations section of the Nanox website at Events and Presentations .
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.
Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI for more accurate diagnostics and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective and user-friendly; Nanox.AI LTD, a subsidiary of Nanox Imaging, with an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision .
Contacts
Investor Contact
Mike Cavanaugh
ICR Healthcare
[email protected]
Media Contact
ICR Healthcare
[email protected]
